1. Clear MoA:
(1) Depleting pathogenesis CD19 high B cells is effective in autoimmune disease treatment.
(2) Anti-CD19 in this Asset has a moderate affinity, which is beneficial to deplete pathological B cells without killing normal B cells.
(3) Anti-CD3 gently activates T cells, so it can reduce CRS.
(4) No FC segment design to reduce toxicity.
(5) PEGylated antibodies can prolong their half-life in humans.
2. Unmet clinical need.
Chinese patients are extremely lack of medicines for the autoimmune disease such as MS. 60% of Chinese MS patients in remission have no appropriate treatment.
3. Excellent safety for treating autoimmune diseases.
(1) With mild T cell activation, asset can reduce CRS.
(2) No Fc related toxicities.
4. High efficacy in-vitro and in-vivo.
(1) Selectively deplete Pathological B cells, whose CD19 is high expression.
(2) Decreased total T cells in spleen.
(3) Decreased Th1 and Th17 in CNS.
(4) pre-EAE administration: Delaying the onset of disease and reducing symptoms.post-EAE administration: Reducing symptoms, still effective after stopping dosing.
5. Extensive GLP tox studies have demonstrated high safety profile of the asset.
6. Asset’s PK is longer than Blincyto due to PEGylation. It is expected to be administrated weekly in clinic.
1. Asset type: PEGylation CD3 + CD19 bsAb
2. Indication: Autoimmune disease
3. Modality: PEG modification bsAb, no Fc
4. Research phase: FDA IND Ready
5. Cooperation demands: License-out or co-development
6. Research progress:
1. The IND application has been submitted to the FDA.
2. GLP toxicity studies in multiple animals has been completed.
3. Pre-EAE and post-EAE administration of Asset showed the effect of delaying the onset of disease and reducing symptoms. It has not been seen in the reported anti-CD20 and anti-CD19 treating EAE animal model.
ComboX is a new brand of ACROBiosystems. ComboX products include our Streptavidin series products, coated plates, isotype controls for antibody and fusion protein drug research, and general-purpose antibodies.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro is ACROBiosystems brand focused on neuroscience research, providing high-quality important proteins including therapeutic and diagnostic research proteins, PFFs and recombinant neuro factors, etc. to advance neuroscience research.
This web search service is supported by Google Inc.